Ultragenyx Stock Plummets 43.49% Following Phase III Trial Failures
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Securities Fraud Investigation: The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Ultragenyx and may file a class action on behalf of investors, aiming to protect their legal rights and recover losses.
- Clinical Trial Failures: On December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic studies failed to meet primary endpoints, resulting in a significant setback for the company in the Osteogenesis Imperfecta treatment space.
- Stock Price Plunge: Following the trial results, Ultragenyx's stock price fell by $14.87, a staggering 43.49% drop, opening at $19.32 on December 29, marking a new 52-week low significantly below the previous low of $25.81.
- Cost Reduction Plan: Ultragenyx disclosed plans to
RARE
$22.78+Infinity%1D
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RARE is 77.08 USD with a low forecast of 35.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 19.720
Low
35.00
Averages
77.08
High
125.00
Current: 19.720
Low
35.00
Averages
77.08
High
125.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
